GB201716181D0 - Recombinant mva with modified hiv-1 env - Google Patents

Recombinant mva with modified hiv-1 env

Info

Publication number
GB201716181D0
GB201716181D0 GBGB1716181.1A GB201716181A GB201716181D0 GB 201716181 D0 GB201716181 D0 GB 201716181D0 GB 201716181 A GB201716181 A GB 201716181A GB 201716181 D0 GB201716181 D0 GB 201716181D0
Authority
GB
United Kingdom
Prior art keywords
env
recombinant mva
modified hiv
hiv
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1716181.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cape Town
Original Assignee
University of Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cape Town filed Critical University of Cape Town
Priority to GBGB1716181.1A priority Critical patent/GB201716181D0/en
Publication of GB201716181D0 publication Critical patent/GB201716181D0/en
Priority to PCT/IB2018/057731 priority patent/WO2019069273A1/en
Priority to CN201880063192.7A priority patent/CN111417405A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1716181.1A 2017-10-04 2017-10-04 Recombinant mva with modified hiv-1 env Ceased GB201716181D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB1716181.1A GB201716181D0 (en) 2017-10-04 2017-10-04 Recombinant mva with modified hiv-1 env
PCT/IB2018/057731 WO2019069273A1 (en) 2017-10-04 2018-10-04 Recombinant mva with modified hiv-1 env
CN201880063192.7A CN111417405A (en) 2017-10-04 2018-10-04 Recombinant MVA with modified HIV-1ENV

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1716181.1A GB201716181D0 (en) 2017-10-04 2017-10-04 Recombinant mva with modified hiv-1 env

Publications (1)

Publication Number Publication Date
GB201716181D0 true GB201716181D0 (en) 2017-11-15

Family

ID=60270478

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1716181.1A Ceased GB201716181D0 (en) 2017-10-04 2017-10-04 Recombinant mva with modified hiv-1 env

Country Status (3)

Country Link
CN (1) CN111417405A (en)
GB (1) GB201716181D0 (en)
WO (1) WO2019069273A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CN1631440A (en) * 2004-11-24 2005-06-29 长春百克药业有限责任公司 Recombined poxvirus vaccine for preventing AIDS
SG10201901735XA (en) * 2014-09-03 2019-03-28 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
WO2016037154A1 (en) * 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use

Also Published As

Publication number Publication date
CN111417405A (en) 2020-07-14
WO2019069273A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
IL253820B (en) Retroviral and lentiviral vectors
IL290258A (en) Recombinant isfahan viral vectors
IL267785A (en) Virus
PL3539822T3 (en) Lashing point
EP3328438A4 (en) Polypeptide monoliths
IL266090A (en) Recombinant bagworm silk
EP3328440A4 (en) Treatment using truncated trk b and trk c antagonists
MA41943A (en) HIV FUSION POLYPEPTIDES
GB201719557D0 (en) Polypeptide
IL273430A (en) Crystal
PT3250234T (en) Recombinant mdv1 and the uses thereof
GB201716181D0 (en) Recombinant mva with modified hiv-1 env
GB201817109D0 (en) Crane
IL261895B (en) Middle point zero reference
GB201721981D0 (en) Fuel
SG10201508927SA (en) Protein crystal
PL3461785T3 (en) Crane
PL3466864T3 (en) Crane
GB201708471D0 (en) Polypeptide
EP3562497A4 (en) Novel recombinant hiv epitopes and uses thereof
GB201717288D0 (en) Hiv vaccine
GB201716047D0 (en) Virus
GB201718200D0 (en) Rochi tips
GB201717167D0 (en) Flippers
GB201708197D0 (en) Scan flag

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)